Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors
- PMID: 36542856
- DOI: 10.1021/jacs.2c10177
Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors
Abstract
Proteolysis targeting chimera (PROTAC) is an emerging protein degradation strategy, which shows excellent advantages in targeting those so-called "undruggable" proteins. However, the potential systemic toxicity of PROTACs caused by undesired off-tissue protein degradation may limit the application of PROTACs in clinical practice. Here we reported a radiotherapy-triggered PROTAC prodrug (RT-PROTAC) activation strategy to precisely and spatiotemporally control protein degradation through X-ray radiation. We demonstrated this concept by incorporating an X-ray inducible phenyl azide-cage to a bromodomain (BRD)-targeting PROTAC to form the first RT-PROTAC. The RT-PROTAC prodrug exhibits little activity but can be activated by X-ray radiation in vitro and in vivo. Activated RT-PROTAC degrades BRD4 and BRD2 with a comparable effect to the PROTAC degrader and shows a synergistic antitumor potency with radiotherapy in the MCF-7 xenograft model. Our work provides an alternative strategy to spatiotemporally control protein degradation in vivo and points to an avenue for reducing the undesired systemic toxicity of PROTACs.
Similar articles
-
Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy.Acta Pharmacol Sin. 2024 Aug;45(8):1740-1751. doi: 10.1038/s41401-024-01266-z. Epub 2024 Apr 12. Acta Pharmacol Sin. 2024. PMID: 38609561
-
Rational Design of Bioorthogonally Activatable PROTAC for Tumor-Targeted Protein Degradation.J Med Chem. 2023 Nov 9;66(21):14843-14852. doi: 10.1021/acs.jmedchem.3c01423. Epub 2023 Oct 23. J Med Chem. 2023. PMID: 37871321
-
In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy.Biomaterials. 2023 Apr;295:122038. doi: 10.1016/j.biomaterials.2023.122038. Epub 2023 Feb 7. Biomaterials. 2023. PMID: 36787659
-
Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity.J Med Chem. 2023 Jul 13;66(13):8428-8440. doi: 10.1021/acs.jmedchem.3c00302. Epub 2023 Jun 14. J Med Chem. 2023. PMID: 37317568 Review.
-
[Advances in targeted delivery of proteolysis targeting chimeras in cancer therapy].Sheng Wu Gong Cheng Xue Bao. 2023 Sep 25;39(9):3628-3643. doi: 10.13345/j.cjb.230006. Sheng Wu Gong Cheng Xue Bao. 2023. PMID: 37805843 Review. Chinese.
Cited by
-
Application of PROTACs in Target Identification and Target Validation.Acta Mater Med. 2024 Feb 21;3(1):72-87. doi: 10.15212/amm-2024-0010. Epub 2024 Mar 21. Acta Mater Med. 2024. PMID: 39373008 Free PMC article.
-
Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies.Acta Pharm Sin B. 2024 Feb;14(2):533-578. doi: 10.1016/j.apsb.2023.09.003. Epub 2023 Sep 12. Acta Pharm Sin B. 2024. PMID: 38322348 Free PMC article. Review.
-
Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy.Acta Pharmacol Sin. 2024 Aug;45(8):1740-1751. doi: 10.1038/s41401-024-01266-z. Epub 2024 Apr 12. Acta Pharmacol Sin. 2024. PMID: 38609561
-
Modular Development of Enzyme-Activatable Proteolysis Targeting Chimeras for Selective Protein Degradation and Cancer Targeting.JACS Au. 2024 May 16;4(7):2564-2577. doi: 10.1021/jacsau.4c00298. eCollection 2024 Jul 22. JACS Au. 2024. PMID: 39055140 Free PMC article.
-
A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapy.Nat Commun. 2024 Aug 4;15(1):6608. doi: 10.1038/s41467-024-50735-w. Nat Commun. 2024. PMID: 39098906 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous